Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight‐Based to Flat‐Dosing Strategy

Read full text Summarise with VIRAT
Authors: Kun Wang, Yuanyuan Shen, Chen Hu, Fengyan Xu, Zhihao Kwok, Qingyu Wang, Yaqi Lin, Yuying Gao, Liang Zhou
Cited by: 0
References: 21

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Serplulimab is a fully humanized anti–PD‐1 monoclonal antibody approved for small‐cell lung cancer and other malignancies. The initial dosing strategy was based on body weight (WT‐based); however, flat‐dosing offers greater convenience and reduced variability. This study characterized the population pharmacokinetics (PopPK) of serplulimab using data from 11 clinical trials and quantitatively evaluated the appropriateness of transitioning from WT‐based to flat‐dose regimens. Serplulimab concentration–time data from 2110 patients were analyzed using nonlinear mixed‐effects modeling. A previously developed two‐compartment model with time‐varying clearance best described the pharmacokinetic (PK) profile. A stepwise forward‐addition and backward‐elimination procedure was used to evaluate covariate effects on PK parameters. Model adequacy was confirmed by diagnostic plots, prediction‐corrected visual predictive checks (pcVPCs), and bootstrap analysis. Simulations compared exposures between 3 mg/kg every 2 weeks (Q2W), 4.5 mg/kg every 3 weeks (Q3W), 200 mg Q2W, and 300 mg Q3W regimens. Body weight and albumin were the main predictors of exposure. Although statistically significant, covariate effects were modest (≤ 20%) and not clinically meaningful, supporting a unified dosing strategy. Simulations showed that flat‐dose regimens achieved exposure comparable to WT‐based dosing, with < 25% differences in median C avg and C max across body‐weight ranges. Exposure–response (E–R) analyses revealed no meaningful association between exposure and outcomes. The PopPK model adequately described serplulimab PK and supports transitioning from WT‐based to flat‐dosing, demonstrating comparable exposure, efficacy, and safety across regimens.

Fields of Study & Subjects

Pharmaceutical studies and practices Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
CPT Pharmacometrics & Systems Pharmacology
Volume
15
Issue
4
Pages
e70204–e70204
Publication date
31 March 2026
Language
EN